27
Mar
2017
Don’t Miss the TR Anniversary Parties in Boston and Seattle
Ferris Bueller once said: “Life moves pretty fast. If you don’t stop and look around once in a while, you could miss it.” Timmerman Report started two years ago. It’s time to thank subscribers, and throw a couple free community parties – one in the East, one in the West. The Boston party will be on Apr. 13, and Seattle’s... Read More
24
Mar
2017
Amgen’s PCSK9 Mixed Bag, Regeneron & GSK’s Genomics Bet, and Healthcare Vote Stalls
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Mar
2017
The Opioid Crisis Needs Biotech. Nektar Drug Is a Half-Step
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Mar
2017
White House Wants to Gut NIH, Allergan’s CRISPR Foray, & New VCs Sprout Up
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Mar
2017
eGenesis Snags $38M to Make CRISPR-modified Pigs for Organ Transplantation
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Mar
2017
Biomatics, Run by Gates Vets, Raises $200M for Genomics & Healthcare Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Mar
2017
Gottlieb on Deck at FDA, Editing Human Embryos, & Gilead Exec Rips PBMs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Mar
2017
Dunsire Joins Xtuit to Fight Microenvironment; Spero Gets $51.7M for Antibiotics
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Mar
2017
Grail’s $900M Haul, Kite’s CAR-T Stands Up 6 Months, & Icahn Returns
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Feb
2017
The Aconcagua Expedition Photos
It was cold enough that my ridiculously fluffy 8,000-meter-rated goose down parka was a must-wear. Wind gusts knocked me off my feet once, and kept the tent flapping all night long. Mountain air was so bone-dry, my boogers turned into gravelly nuggets. Tolerance for grime was a must, given that we were wearing the same sweat-encrusted socks and underwear every day. Sleeping... Read More
27
Feb
2017
You Can’t Do That With RNA, Can You? Arrakis Tests Small Molecules in a New Way
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Feb
2017
BMS on the Block (Maybe), Sarepta Sells a Golden Ticket to Gilead & a Summit Pic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Feb
2017
Join Me at BIO-Europe Spring Mar. 21 in Barcelona To Talk EU Entrepreneurship
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jan
2017
J&J Reels in Actelion for $30B, Celgene Snaps up Delinia, and an IPO Flurry
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jan
2017
Women Making Progress, Very Slowly, On Biotech Boards, Report Says
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jan
2017
Who’s In and Out on Trump’s Health Team, BMS Cedes Ground to Merck, & CRE Superbugs on the Move
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Jan
2017
Takeda Leans on a Little Guy, Ovid Therapeutics, to Go the Distance With an Epilepsy Drug
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jan
2017
Takeda Takes Out Ariad, Illumina Plants a $100 Genome Stake, & Anti-Vaxxer Nuzzles With Trump
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Jan
2017
Amgen Wins PCSK9 Duel, Jenkins’ Parting Shot, and Obamacare’s Last Stand
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jan
2017
Neon Therapeutics Gets $70M to Push Neoantigen Cancer Vaccines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.